Insights from a pharmacometric analysis of HDMTX in adults with cancer: Clinically relevant covariates for application in precision dosing

Autor: Manuel Ibarra, Ryan Combs, Zachary L. Taylor, Laura B. Ramsey, Torben Mikkelsen, Randal K. Buddington, Jesper Heldrup, Jason N. Barreto, Martin Guscott, Jennifer Lowe, Charles Hurmiz, Suresh Marada, Scott C. Howard, Paula Schaiquevich

Publikováno v: Ibarra, M, Combs, R, Taylor, Z L, Ramsey, L B, Mikkelsen, T, Buddington, R K, Heldrup, J, Barreto, J N, Guscott, M, Lowe, J, Hurmiz, C, Marada, S, Howard, S C & Schaiquevich, P 2023, ' Insights from a pharmacometric analysis of HDMTX in adults with cancer : Clinically relevant covariates for application in precision dosing ', British Journal of Clinical Pharmacology, vol. 89, no. 2, pp. 660-671 . https://doi.org/10.1111/bcp.15506

AIMS: High-dose methotrexate (HDMTX) is an essential part of the treatment of several adult and paediatric malignancies. Despite meticulous supportive care during HDMTX administration, severe toxicities, including acute kidney injury (AKI), may occur

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33d34f27571fe66d72b1e347edf0760e
https://doi.org/10.1111/bcp.15506